Funding for eye drug decreases wait times and treatment costs

by Karen Brown / 11 October, 2018
Wait times and treatment costs for patients with degenerative vision set to decrease with Government funding of new eye drug. Photo/Getty

Wait times and treatment costs set to decrease for patients with degenerative eye disease following Government funding. Photo/Getty

RelatedArticlesModule - Vision

Government funding for an eye disease drug has decreased wait times and the cost of treatment, an eye specialist says.

Macular degeneration is disease which can cause loss of vision in the centre of the field of vision. In dry macular degeneration, the centre of the retina deteriorates. With wet macular degeneration, leaky blood vessels grow under the retina.

Auckland businessman John Gilbert found out in his early 50s he had early onset macular degeneration.

Under the care of his eye specialist Dianne Sharp, Mr Gilbert started out on Avastin, a bowel cancer drug funded by district health boards and also used off-label for eyes.

When that proved less successful, he moved to Lucentis, which was not funded at the time for eye care, but has been since 2013, as a second-line treatment.

It meant he was having to pay about $1800 a time, Mr Gilbert said.

"I'd usually have an eye injection sort of six weeks apart and at that rate try and make it eight weeks apart, which is not necessarily doing you any good, but you just don't want to keep paying lots of money."

Mr Gilbert was on Lucentis for two or three years before a new drug came along, Eylea. He said he was probably one of the first patients in New Zealand to take it.

The price was about the same per injection but it was "meant to be a more advanced solution".

Now both eyes now needed treatment, meaning Mr Gilbert faced an even bigger bill.

The maker of Eylea, Bayer, agreed to subsidise every second treatment, but it was still a major cost.

"Every six weeks it ended up being $1800 or $3600. It was either one or the other for a period. And that was quite tough because that's a lot of money."

But Mr Gilbert was never in any doubt about the need, which he said is imperative, to keep his eyesight if at all possible.

"I'd like to be able to drive, I'd like to get out and walk along the beach and play a little bit of sport. So there's a whole lot of reasons why I'd like to keep my eyesight."

In June, drug-buyer Pharmac funded Eylea as a second-line treatment for use after the cancer drug Aventis, which has been used successfully around the world for years.

Dr Sharp said Avastin worked well for the vast majority of people.

"But there are a group of people for whom it doesn't work who have sub-optimal response, or it [the eye] continues to leak and it continues to deteriorate and they may well respond to these newer drugs.

"It's really important to have good management of their disease, stabilise it and then be able to extend the time between their visits, and then we don't need to have so many visits. So for some people switching to Eylea is going to allow us to really do that."

Ministry of Health chief medical officer Andrew Simpson said the number of people nationally waiting had dropped from 10,000 last year to 2200 in most recent figures.

Pharmac chief executive Sarah Fitt would not disclose the cost of the new medicine but said it funded Eylea as part of a bundle with another medicine, a blood-thinner.

Ms Fitt said one of the advantages of the drug was the possibility that it could help with "some of the capacity issues".

This article was originally published by RNZ.

MostReadArticlesCollectionWidget - Most Read - Used in articles
AdvertModule - Advert - M-Rec / Halfpage


Vincent O’Malley: Why we need to open up about past Māori and Pākehā conflict
106234 2019-05-26 00:00:00Z History

Vincent O’Malley: Why we need to open up about pas…

by Sally Blundell

Calls are growing for us to take a more honest look at our past, particularly the wars over land and power that shaped the country.

Read more
Scott Morrison: How a 'doomed' PM stormed the country with one killer line
106291 2019-05-26 00:00:00Z World

Scott Morrison: How a 'doomed' PM stormed the coun…

by Bernard Lagan

As Australia’s tourism tsar 13 years ago, Scott Morrison oversaw the rollicking “So where the bloody hell are you?’’ ad campaign.

Read more
What you need to know about knee replacements
105774 2019-05-26 00:00:00Z Health

What you need to know about knee replacements

by Ruth Nichol

Replacement knee joints are giving thousands of Kiwis decades of service, but don’t rush to get one.

Read more
How a hit romcom took indigenous Aussie star Miranda Tapsell back to her roots
106072 2019-05-25 00:00:00Z Movies

How a hit romcom took indigenous Aussie star Miran…

by Russell Baillie

Miranda Tapsell tells Russell Baillie how she came up with Top End Wedding and why its Northern Territory setting means so much.

Read more
The link between cardiovascular health and dementia
105915 2019-05-25 00:00:00Z Health

The link between cardiovascular health and dementi…

by Nicky Pellegrino

New research into the brain has found that cardiovascular ill health is linked to cognitive decline and dementia.

Read more
Following the call of New Zealand's abandoned freezing works
106317 2019-05-25 00:00:00Z Life in NZ

Following the call of New Zealand's abandoned free…

by John Summers

John Summers wonders if his abiding interest in New Zealand’s abandoned freezing works is actually a long farewell to his grandfather.

Read more
Tech Week: Time to celebrate Aotearoa’s own overlooked moonshot
106359 2019-05-25 00:00:00Z Tech

Tech Week: Time to celebrate Aotearoa’s own overlo…

by Peter Griffin

“We bow down to this idea of Elon Musk or Jeff Bezos going to Mars, when here in our own country, we had the equivalent."

Read more
Kiwi composer John Rimmer: An instrumental figure
106331 2019-05-24 11:09:35Z Music

Kiwi composer John Rimmer: An instrumental figure

by Elizabeth Kerr

Contemporaries and students are paying tribute to composer John Rimmer and his musical legacy.

Read more